Citations

Clear

1422 citation(s) found for "White, JB".

Assessing Femoral Trochlear Morphologic Features on Cross-Sectional Imaging Before Trochleoplasty: Dejour Classification Versus Quantitative Measurement
Nacey, Nicholas C. , Fox, Michael G. , Luce, Barrett N., Boatman, Dustin M., Diduch, David R.

Mayo Clinic

American Journal of Roentgenology | June 6, 2020 | Volume: 215 | Issue: 2 | Pages: 458-464

10.2214/ajr.19.22400 | PMID 32507014 Get It

A Comparative Effectiveness Study of Newborn Screening Methods for Four Lysosomal Storage Disorders
Sanders, Karen A., Gavrilov, Dimitar K. , Oglesbee, Devin , Raymond, Kimiyo , Tortorelli, Silvia , Hopwood, John J., Lorey, Fred, Majumdar, Ramanath, Kroll, Charles, McDonald, Amber , Lacey, Jean M., Turgeon, Coleman , Tucker, Justin N. , Tang, Hao , Currier, Robert J. , Isaya, Grazia , Rinaldo, Piero, Matern, Dietrich , Raymond, Kimiyo M, Kroll, Charles A, McDonald, Amber M, Turgeon, Coleman T, Oglesbee, Devin , Currier, Robert

Mayo Clinic

International Journal of Neonatal Screening | June 1, 2020 | Volume: 6 | Issue: 2 | Pages: 44

10.3390/ijns6020044 | PMID 32802993 Get It

Newborn screening for one or more lysosomal disorders has been implemented in several US states, Japan and Taiwan by multiplexed enzyme assays using either tandem mass spectrometry or digital microfluidics. Another multiplex assay making use of immunocapture technology has also been proposed. To investigate the potential variability in performance of these analytical approaches, we implemented three high-throughput screening assays for the simultaneous screening for four lysosomal disorders: Fabry disease, Gaucher disease, mucopolysaccharidosis type I, and Pompe disease. These assays were tested in a prospective comparative effectiveness study using nearly 100,000 residual newborn dried blood spot specimens. In addition, 2nd tier enzyme assays and confirmatory molecular genetic testing were employed. Post-analytical interpretive tools were created using the software Collaborative Laboratory Integrated Reports (CLIR) to determine its ability to improve the performance of each assay vs. the traditional result interpretation based on analyte-specific reference ranges and cutoffs. This study showed that all three platforms have high sensitivity, and the application of CLIR tools markedly improves the performance of each platform while reducing the need for 2nd tier testing by 66% to 95%. Moreover, the addition of disease-specific biochemical 2nd tier tests ensures the lowest false positive rates and the highest positive predictive values for any platform.
PROTOCOL: When and how to replicate systematic reviews
Karunananthan, Sathya , Maxwell, Lara , Pardo, Jordi Pardo , Avey, Marc T. , Baptiste-Ngobi, John, Batista, Ricardo , Curran, Janet , Ghogomu, Elizabeth Tanjong , Graham, Ian D. , Ioannidis, John P. A. , Jordan, Zoe , Jull, Janet , Lyddiatt, Anne , Pottie, Kevin , Shamseer, Larissa , Shea, Beverley , Siontis, Konstantinos C. , Tschirhart, Naomi , Wells, George A. , Ioannidis, John P A , Pottie, Kevin , Welch, Vivian Andrea , Petkovic, Jennifer , Rader, Tamara , Batista, Ricardo, Grimshaw, Jeremy , Moher, David , Petticrew, Mark P. , G, Gabriel Rada , Vachon, Brigitte , White, Howard , Tugwell, Peter

Mayo Clinic

Campbell Systematic Reviews | May 28, 2020 | Volume: 16 | Issue: 2 | Pages: No page available

10.1002/cl2.1087 | PMID 37131421 Get It

Abstract This is a protocol for a co‐registered Cochrane and Campbell Review (Methodology). The objectives are as follows: To identify, describe and assess methods for: when to replicate a systematic review; how to replicate a systematic review.
Associations between Genetically Predicted Blood Protein Biomarkers and Pancreatic Cancer Risk
Zhu, Jingjing , Shu, Xiao-Ou , Bao, Jiandong , Milne, Roger L. , Du, Mengmeng , Goodman, Phyllis J. , Li, Donghui , Bracci, Paige M. , Gallinger, Steven , Arslan, Alan A. , Scélo, Ghislaine , Visvanathan, Kala , Haiman, Christopher A. , Petersen, Gloria M. , Wu, Lang , Shu, Xiao-Ou , Bao, Jiandong , Milne, Roger L , Malats, Nuria , Duell, Eric J , Li, Donghui , Katzke, Verena , Van Den Eeden, Stephen K , Arslan, Alan A , Canzian, Federico , Yu, Herbert , Klein, Alison P , Visvanathan, Kala , Guo, Xingyi , Liu, Duo, Giles, Graham G. , Wu, Chong , White, Emily , Risch, Harvey A. , Malats, Núria , Duell, Eric J. , Neale, Rachel Ε. , Canzian, Federico , Kooperberg, Charles , Freeman, Laura E. Beane , Marchand, Loı̈c Le , Yu, Kai , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Cai, Qiuyin , Long, Jirong , Zheng, Wei

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 21, 2020 | Volume: 29 | Issue: 7 | Pages: 1501-1508

10.1158/1055-9965.epi-20-0091 | PMID 32439797 Get It

Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, with few known risk factors and biomarkers. Several blood protein biomarkers have been linked to PDAC in previous studies, but these studies have assessed only a limited number of biomarkers, usually in small samples. In this study, we evaluated associations of circulating protein levels and PDAC risk using genetic instruments. Methods: To identify novel circulating protein biomarkers of PDAC, we studied 8,280 cases and 6,728 controls of European descent from the Pancreatic Cancer Cohort Consortium and the Pancreatic Cancer Case-Control Consortium, using genetic instruments of protein quantitative trait loci. Results: We observed associations between predicted concentrations of 38 proteins and PDAC risk at an FDR of < 0.05, including 23 of those proteins that showed an association even after Bonferroni correction. These include the protein encoded by ABO, which has been implicated as a potential target gene of PDAC risk variant. Eight of the identified proteins (LMA2L, TM11D, IP-10, ADH1B, STOM, TENC1, DOCK9, and CRBB2) were associated with PDAC risk after adjusting for previously reported PDAC risk variants (OR ranged from 0.79 to 1.52). Pathway enrichment analysis showed that the encoding genes for implicated proteins were significantly enriched in cancer-related pathways, such as STAT3 and IL15 production. Conclusions: We identified 38 candidates of protein biomarkers for PDAC risk. Impact: This study identifies novel protein biomarker candidates for PDAC, which if validated by additional studies, may contribute to the etiologic understanding of PDAC development.
Orthopaedic Documentation and Coding Primer for Telemedicine and Electronic Patient Communication for the COVID-19 Pandemic
Hinckley, Nathaniel B. , Henley, M. Bradford , McIntyre, Louis F. , Stiefel, Eric C. , Davidson, James , Chhabra, Anikar , McIntyre, Louis , Stiefel, Eric , Chhabra, Anikar

Mayo Clinic

Journal of Bone and Joint Surgery | May 13, 2020 | Volume: 102 | Issue: 13 | Pages: 1105-1108

10.2106/jbjs.20.00649 | PMID 32618907 Get It

➢ The coronavirus disease 2019 (COVID-19) crisis has disrupted health care in the United States and globally, and the ability to treat patients as we did in the prepandemic environment has changed. The safety of patients and providers, the avoidance of unnecessary exposure, and the cancellation of elective procedures have prompted the use of telemedicine. In addition, many large institutions are without a functioning videoconferencing platform and the use of telephone visits has become essential. ➢ Several important changes have been made by the Centers for Medicare & Medicaid Services to facilitate ease of access to telemedicine during the COVID-19 pandemic, including alternate place of service codes, visit time associated with evaluation and management services, and new Current Procedural Terminology codes for virtual visits with new patients. ➢ Although telemedicine visits do not allow for a hands-on physical examination, it is prudent for the medical provider to understand and learn the breadth of examination that may take place through an audio and video (when possible)-enabled virtual visit.
Improving Resident Satisfaction with Post-Hospitalization Follow-up at Mayo Clinic Florida
Melody, Megan , Espinosa, Samantha , Mareth, Karl , Gardner, Lindsay B., Heckman, Alexander , Mechtler, Annamaria G., Killebrew, SeQuoya R., Dudgeon, Matthew, White, Richard O. , Speicher, Leigh L.

Mayo Clinic

No container title available | May 11, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.158921583.30982457 Get It

Rationale, aims, and objectives: Post-hospitalization follow-up within 30 days following discharge has been shown to positively impact time to readmission, healthcare costs, and patient self-reported adherence and satisfaction. We aimed to improve resident satisfaction with the process of establishing post-hospitalization, primary care provider (PCP) follow-up. Methods: In this quality improvement study we surveyed all internal medicine residents at our institution regarding their satisfaction with the process of establishing PCP follow-up at the time of hospital discharge. A streamlined process was developed and two subsequent interventions were enacted; a dedicated teaching session and distribution of pocket cards outlining the process. Residents were then surveyed following each intervention to assess for impact on overall satisfaction and burden of work. Results: Initially, 77.3% of residents were not satisfied with the process of establishing post-hospitalization PCP follow-up. Following the first intervention there was a trend towards increasing satisfaction rates by 16.7% (p= 0.20), and after the second intervention there was a statistically significant increase in satisfaction rates from baseline by 44% (p= 0.007). There was also a reduction in the feeling of workload burden associated with establishing PCP follow-up from 32% to 25%, and over 67% of participants either agreed or strongly agreed that the workload was not too burdensome. Conclusion: This quality improvement initiative established that resident physicians at our institution previously found the process of establishing PCP follow-up at the time of patient discharge both confusing and burdensome. Through the implementation of our interventions we were able to achieve our aims of improving resident satisfaction.
Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or Vomiting
Navari, Rudolph M. , Pywell, Cameron, White, Patrick , Dodge, Andrew , Albany, Costantine , Loprinzi, Charles L. , Dodge, Andrew B, Le‐Rademacher, Jennifer

Mayo Clinic

JAMA Oncology | May 7, 2020 | Volume: 6 | Issue: 6 | Pages: 895

10.1001/jamaoncol.2020.1052 | PMID 32379269 Get It

Mortality and Paclitaxel-Coated Devices
Rocha‐Singh, Krishna J. , Duval, Sue , Schneider, Peter A. , Ansel, Gary M. , Lyden, Sean P. , Ioannidis, John P. A. , Tzafriri, Abraham R. , Edelman, Elazer R. , Granada, Juan F. , Misra, Sanjay , Misra, Sanjay , Ioannidis, John P A , Jaff, Michael R. , Mullin, Christopher M., Misra, Sanjay, White, Christopher J. , Beckman, Joshua A.

Mayo Clinic

Circulation | May 6, 2020 | Volume: 141 | Issue: 23 | Pages: 1859-1869

10.1161/circulationaha.119.044697 | PMID 32370548 Get It

Background: Paclitaxel-containing devices (PTXDs) significantly reduce reintervention in patients with symptomatic femoropopliteal peripheral artery disease. A recent aggregate-data meta-analysis reported increased late mortality in patients with peripheral artery disease treated with PTXDs. We performed an individual patient data meta-analysis to evaluate mortality. Methods: Manufacturers of US Food and Drug Administration–approved and commercially available devices in the United States provided deidentified individual patient data for independent analysis. Cox proportional hazards 1-stage meta-analysis models using intention-to-treat methods were used for the primary analysis. A secondary analysis of recovered missing vital status data was performed. The impact of control crossover to PTXDs, cause-specific mortality, and drug dose mortality were assessed. Results: A total of 2185 subjects and 386 deaths from 8 PTXD trials with 4-year median follow-up were identified. The primary analysis indicated a 38% (95% CI, 6% to 80%) increased relative mortality risk, corresponding to 4.6% absolute increase, at 5 years associated with PTXD use. Control and treatment arm loss to follow-up and withdrawal were 24% and 23%, respectively. With inclusion of recovered vital status data, the excess relative mortality risk was 27% (95% CI, 3%–58%). This observation was consistent across various scenarios, including as-treated analyses, with no evidence of increased risk over time with PTXDs. Mortality risk tended to be increased for all major causes of death. There were no subgroup differences. No drug dose–mortality association was identified. Conclusions: This individual patient data meta-analysis, based on the most complete available data set of mortality events from PTXD randomized controlled trials, identified an absolute 4.6% increased mortality risk associated with PTXD use.
International Organization for the Study of IBD Recommendations for Surgery in Patients With IBD During the Coronavirus Disease 2019 Pandemic
Remzi, Feza H. , Panís, Yves , Spinelli, Antonino , Mantzaris, Gerassimos J. , Söderholm, Johan D. , D’Hoore, André , Bemelman, Willem A. , Pembérton, John H., Tiret, Emmanuel , Öresland, Tom , Fleshner, Phillip , Spinelli, Antonino , Kotze, Paulo Gustavo , Yamamoto, Takayuki

Mayo Clinic

Diseases of the Colon & Rectum | April 30, 2020 | Volume: 63 | Issue: 7 | Pages: 870-873

10.1097/dcr.0000000000001718 | PMID 32355056 Get It

The Truly Functional Heart Team: The Devil Is in the Details
Holmes, David R. , Mack, Michael J.

Mayo Clinic

Journal of the American Heart Association | April 20, 2020 | Volume: 9 | Issue: 8 | Pages: No page available

10.1161/jaha.120.016306 | PMID 32308107 Get It